New evidence reveals tamoxifen reduces breast cancer rates by nearly a third for 20 years
The preventive effect of breast cancer drug 'tamoxifen' remains virtually constant for at least 20 years - with rates reduced by around 30 per cent - new analysis published in The Lancet Oncology reveals.
Dec 11, 2014
0
0